Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -103.29% is 71% below its 5-year average of -60.54%, near the low end of its 5-year range (-103.29%–-24.01%).
30.29% below its 12-month average of -79.28%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.46%.
RETURN ON ASSETS (ROA)
-103.29%
RETURN ON ASSETS (ROA) AVG TTM
-79.28%
RETURN ON ASSETS (ROA) AVG 3Y
-61.36%
RETURN ON ASSETS (ROA) AVG 5Y
-60.54%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-30.29%
CURRENT VS 3Y AVG
-68.33%
CURRENT VS 5Y AVG
-70.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
-292.07%
vs the sector median at left
Faeth Therapeutics, Inc.
Market Cap
$698.60M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
Market Cap
$707.86M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$688.14M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$709.33M
Return on Assets (ROA)
2.24%
TTM Avg
3.98%
3Y Avg
2.51%
5Y Avg
4.09%
Market Cap
$719.64M
Return on Assets (ROA)
-59.88%
TTM Avg
-116.93%
3Y Avg
-132.27%
5Y Avg
-105.87%
Market Cap
$675.41M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$734.10M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
Market Cap
$749.55M
Return on Assets (ROA)
-42.53%
TTM Avg
-41.06%
3Y Avg
-49.54%
5Y Avg
-47.47%
Market Cap
$643.37M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $698.60M | -103.29% | -79.28% | -61.36% | -60.54% |
| Helus Pharma Inc. (HELP)vs › | $707.86M | -70.67% | -51.05% | -54.02% | -55.25% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -82.36% | -56.97% | -52.21% | -45.34% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.24% | 3.98% | 2.51% | 4.09% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -59.88% | -116.93% | -132.27% | -105.87% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -36.37% | -26.71% | -31.04% | -27.33% |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -38.01% | -251.96% | -211.47% | -174.45% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -42.53% | -41.06% | -49.54% | -47.47% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -37.63% | -55.16% | -41.63% | -48.17% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -13.75% | -12.94% | -23.44% | -17.36% |
ROA
-103.3%
ROE
-113.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -92.07% |
| 2024-12-31 | -66.48% |
| 2023-12-31 | -45.85% |
| 2022-12-31 | -41.05% |
| 2021-12-31 | -24.01% |
| 2020-12-31 | -93.80% |
| 2019-12-31 | -1375.51% |
| 2018-12-31 | -704.81% |
